Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease

Neuropharmacology

Volumn 62, Issue 7, 2012, Pages 2154-2168

  Collins, Louise M ^a   Toulouse, André ^a   Connor, Thomas J ^b   Nolan, Yvonne M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cytokines; Immunomodulatory therapies; Microglia; Neuroinflammation; Parkinson's disease; Systemic inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIPARKINSON AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CELECOXIB; DEXAMETHASONE; GLATIRAMER; GLUCOCORTICOID; GLUTATHIONE; I KAPPA B KINASE INHIBITOR; IBUPROFEN; ICOSANOID; IMMUNOMODULATING AGENT; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA; MINOCYCLINE; NISOXETINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SALICYLIC ACID; SALMETEROL; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

BLOOD BRAIN BARRIER; CELL LEVEL; CELL TYPE; CENTRAL INFLAMMATION; CHRONIC INFLAMMATION; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG MECHANISM; ENCEPHALITIS; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; HUNTINGTON CHOREA; IDIOPATHIC DISEASE; IMMUNOMODULATION; INFLAMMATION; INTRAUTERINE INFECTION; LYMPHOCYTIC INFILTRATION; MEMBRANE PERMEABILITY; MICROGLIA; NERVE CELL LESION; NERVE CELL STIMULATION; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRENATAL SYSTEMIC INFECTION; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; REVIEW; RNA INTERFERENCE; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; SYSTEMIC DISEASE; SYSTEMIC INFLAMMATION; T LYMPHOCYTE;

EID: 84859107546     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.01.028     Document Type: Review

References (252)

1. D.D. Alasia, G.A. Asekomeh, and C.N. Unachuku Parkinsonism induced by sepsis: a case report Niger. J. Med. 15 2006 333 336
2. J. Anrather, G. Racchumi, and C. Iadecola NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox J. Biol. Chem. 281 2006 5657 5667 (Pubitemid 43847663)
3. S.H. Appel, D.R. Beers, and J.S. Henkel T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol. 31 2010 7 17
4. T. Arimoto, D.Y. Choi, X. Lu, M. Liu, X.V. Nguyen, N. Zheng, C.A. Stewart, H.C. Kim, and G. Bing Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra Neurobiol. Aging 28 2006 894 906
5. N. Arlicot, A. Katsifis, L. Garreau, F. Mattner, J. Vergote, S. Duval, I. Kousignian, S. Bodard, D. Guilloteau, and S. Chalon Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activation Eur. J. Nucl. Med. Mol. Imaging 35 2008 2203 2211
6. R. Arnon, and R. Aharoni Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications Proc. Natl. Acad. Sci. U. S. A. 101 2004 14593 14598 (Pubitemid 39346729)
7. K. Asadullah, W. Sterry, and H.D. Volk Interleukin-10 therapy - review of a new approach Pharmacol. Rev. 55 2003 241 269 (Pubitemid 36666048)
8. N. Aubin, O. Curet, A. Deffois, and C. Carter Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice J. Neurochem. 71 1998 1635 1642 (Pubitemid 28443036)
9. R.B. Banati, S.E. Daniel, and S.B. Blunt Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease Mov Disord. 13 1998 221 227 (Pubitemid 28127795)
10. W.A. Banks, and S.M. Robinson Minimal penetration of lipopolysaccharide across the murine blood-brain barrier Brain Behav. Immun. 24 2010 102 109
11. C. Barcia, C.M. Ros, V. Annese, A. Gomez, F. Ros-Bernal, D. Aguado-Yera, M.E. Martinez-Pagan, V. de Pablos, E. Fernandez-Villalba, and M.T. Herrero IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease Cell Death Dis. 2 2011 e142
12. J. Bas, M. Calopa, M. Mestre, D.G. Mollevi, B. Cutillas, S. Ambrosio, and E. Buendia Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism J. Neuroimmunol. 113 2001 146 152 (Pubitemid 32008680)
13. M. Bauer, N. Kinkl, A. Meixner, E. Kremmer, M. Riemenschneider, H. Forstl, T. Gasser, and M. Ueffing Prevention of interferon-stimulated gene expression using microRNA-designed hairpins Gene Ther. 16 2009 142 147
14. L.M. Bekris, I.F. Mata, and C.P. Zabetian The genetics of Parkinson disease J. Geriatr. Psychiatry Neurol. 23 2010 228 242
15. E.J. Benner, R.L. Mosley, C.J. Destache, T.B. Lewis, V. Jackson-Lewis, S. Gorantla, C. Nemachek, S.R. Green, S. Przedborski, and H.E. Gendelman Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 101 2004 9435 9440 (Pubitemid 38812892)
16. E.J. Benner, R. Banerjee, A.D. Reynolds, S. Sherman, V.M. Pisarev, V. Tsiperson, C. Nemachek, P. Ciborowski, S. Przedborski, R.L. Mosley, and H.E. Gendelman Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons PLoS One 3 2008 e1376
17. D. Beraud, M. Twomey, B. Bloom, A. Mittereder, V. Ton, K. Neitzke, S. Chasovskikh, T.R. Mhyre, and K.A. Maguire-Zeiss Alpha-Synuclein alters toll-like receptor expression Front. Neurosci. 5 2011 80
18. A. Bernardo, M.A. Ajmone-Cat, L. Gasparini, E. Ongini, and L. Minghetti Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen J. Neurochem. 92 2005 895 903 (Pubitemid 40229562)
19. M. Bialecka, M. Kurzawski, G. Klodowska-Duda, G. Opala, S. Juzwiak, G. Kurzawski, E.K. Tan, and M. Drozdzik CARD15 variants in patients with sporadic Parkinson's disease Neurosci. Res. 57 2007 473 476 (Pubitemid 46283073)
20. C.M. Blatteis Role of the OVLT in the febrile response to circulating pyrogens Prog. Brain Res. 91 1992 409 412
21. M.L. Block, and J.S. Hong Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism Prog. Neurobiol. 76 2005 77 98 (Pubitemid 41242883)
22. D. Blum-Degen, T. Muller, W. Kuhn, M. Gerlach, H. Przuntek, and P. Riederer Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients Neurosci. Lett. 202 1995 17 20
23. A. Boireau, F. Bordier, P. Dubedat, C. Peny, and A. Imperato Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice Neurosci. Lett. 234 1997 123 126 (Pubitemid 27452108)
24. G. Boka, P. Anglade, D. Wallach, F. Javoy-Agid, Y. Agid, and E.C. Hirsch Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease Neurosci. Lett. 172 1994 151 154 (Pubitemid 24178765)
25. K. Bossers, K.T. Wirz, G.F. Meerhoff, A.H. Essing, J.W. van Dongen, P. Houba, C.G. Kruse, J. Verhaagen, and D.F. Swaab Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease Brain 133 2010 3699 3723
26. H. Braak, K. Del Tredici, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2003 197 211 (Pubitemid 36007810)
27. V. Brochard, B. Combadiere, A. Prigent, Y. Laouar, A. Perrin, V. Beray-Berthat, O. Bonduelle, D. Alvarez-Fischer, J. Callebert, J.M. Launay, C. Duyckaerts, R.A. Flavell, E.C. Hirsch, and S. Hunot Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease J. Clin. Invest. 119 2009 182 192
28. B. Brodacki, J. Staszewski, B. Toczylowska, E. Kozlowska, N. Drela, M. Chalimoniuk, and A. Stepien Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism Neurosci. Lett. 441 2008 158 162
29. D.M. Bronstein, I. Perez-Otano, V. Sun, S.B. Mullis Sawin, J. Chan, G.C. Wu, P.M. Hudson, L.Y. Kong, J.S. Hong, and M.K. McMillian Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures Brain Res. 704 1995 112 116
30. A.M. Butt ATP: a ubiquitous gliotransmitter integrating neuron-glial networks Semin. Cell Dev. Biol. 22 2011 205 213
31. J.J. Cao, K.S. Li, and Y.Q. Shen Activated immune cells in Parkinson's disease J. Neuroimmune Pharmacol. 6 2011 323 329
32. P.M. Carvey, Q. Chang, J.W. Lipton, and Z. Ling Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease Front. Biosci. 8 2003 s826 837
33. A. Castano, A.J. Herrera, J. Cano, and A. Machado The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma J. Neurochem. 81 2002 150 157 (Pubitemid 34808862)
34. R.K. Chaturvedi, and M.F. Beal PPAR: a therapeutic target in Parkinson's disease J. Neurochem. 106 2008 506 518
35. F. Chauveau, H. Boutin, N. Van Camp, F. Dolle, and B. Tavitian Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers Eur. J. Nucl. Med. Mol. Imaging 35 2008 2304 2319
36. H. Chen, E. Jacobs, M.A. Schwarzschild, M.L. McCullough, E.E. Calle, M.J. Thun, and A. Ascherio Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease Ann. Neurol. 58 2005 963 967 (Pubitemid 41746889)
37. H. Chen, E.J. O'Reilly, M.A. Schwarzschild, and A. Ascherio Peripheral inflammatory biomarkers and risk of Parkinson's disease Am. J. Epidemiol. 167 2008 90 95
38. J.H. Chung, A.Y. Seo, S.W. Chung, M.K. Kim, C. Leeuwenburgh, B.P. Yu, and H.Y. Chung Molecular mechanism of PPAR in the regulation of age-related inflammation Ageing Res. Rev. 7 2008 126 136
39. Y.C. Chung, H.W. Ko, E. Bok, E.S. Park, S.H. Huh, J.H. Nam, and B.K. Jin The role of neuroinflammation on the pathogenesis of Parkinson's disease BMB Rep. 43 2010 225 232
40. F. Cicchetti, A.L. Brownell, K. Williams, Y.I. Chen, E. Livni, and O. Isacson Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging Eur. J. Neurosci. 15 2002 991 998 (Pubitemid 35463634)
41. G. Comi, J.A. Cohen, D.L. Arnold, D. Wynn, and M. Filippi Phase III dose-comparison study of glatiramer acetate for multiple sclerosis Ann. Neurol. 69 2011 75 82
42. Crampton, S.J., Collins, L.M., Toulouse, A., Nolan, Y.M., O'Keeffe, G.W., in press. Exposure of foetal neural progenitor cells to IL-1β impairs their proliferation and alters their differentiation - a role for maternal inflammation? J. Neurochem.
43. E. Croisier, L.B. Moran, D.T. Dexter, R.K. Pearce, and M.B. Graeber Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition J. Neuroinflammation 2 2005 14
44. S. Crotty, P. Fitzgerald, E. Tuohy, D.M. Harris, A. Fisher, A. Mandel, A.E. Bolton, A.M. Sullivan, and Y. Nolan Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease Eur. J. Neurosci. 27 2008 294 300
45. D.J. Cua, B. Hutchins, D.M. LaFace, S.A. Stohlman, and R.L. Coffman Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis J. Immunol. 166 2001 602 608 (Pubitemid 32038483)
46. C. Cunningham, S. Campion, J. Teeling, L. Felton, and V.H. Perry The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I: C) Brain Behav. Immun. 21 2007 490 502 (Pubitemid 46528682)
47. C. Cunningham, S. Campion, K. Lunnon, C.L. Murray, J.F. Woods, R.M. Deacon, J.N. Rawlins, and V.H. Perry Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease Biol. Psychiatry 65 2009 304 312
48. R. Dantzer Cytokine, sickness behavior, and depression Immunol. Allergy Clin. North Am. 29 2009 247 264
49. D. Davalos, J. Grutzendler, G. Yang, J.V. Kim, Y. Zuo, S. Jung, D.R. Littman, M.L. Dustin, and W.B. Gan ATP mediates rapid microglial response to local brain injury in vivo Nat. Neurosci. 8 2005 752 758 (Pubitemid 43085841)
50. T. Dehmer, M.T. Heneka, M. Sastre, J. Dichgans, and J.B. Schulz Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation J. Neurochem. 88 2004 494 501 (Pubitemid 38084565)
51. M. Deleidi, P.J. Hallett, J.B. Koprich, C.Y. Chung, and O. Isacson The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration J. Neurosci. 30 2010 16091 16101
52. M. Delgado, and D. Ganea Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation FASEB J. 17 2003 944 946
53. M. Delgado, E. Gonzalez-Rey, and D. Ganea The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells J. Immunol. 175 2005 7311 7324 (Pubitemid 41713427)
54. A. Denes, P. Thornton, N.J. Rothwell, and S.M. Allan Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation Brain Behav. Immun. 24 2010 708 723
55. A.M. Depino, C. Earl, E. Kaczmarczyk, C. Ferrari, H. Besedovsky, A. del Rey, F.J. Pitossi, and W.H. Oertel Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease Eur. J. Neurosci. 18 2003 2731 2742 (Pubitemid 37542126)
56. D.T. Dexter, F.R. Wells, A.J. Lees, F. Agid, Y. Agid, P. Jenner, and C.D. Marsden Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease J. Neurochem. 52 1989 1830 1836 (Pubitemid 19140770)
57. V. Di Matteo, M. Pierucci, G. Di Giovanni, A. Di Santo, A. Poggi, A. Benigno, and E. Esposito Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study Brain Res. 1095 2006 167 177 (Pubitemid 43884742)
58. D.A. Di Monte The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2 2003 531 538 (Pubitemid 36994992)
59. F.D. Dick Parkinson's disease and pesticide exposures Br. Med. Bull. 79-80 2006 219 231
60. E. Diguet, P.O. Fernagut, X. Wei, Y. Du, R. Rouland, C. Gross, E. Bezard, and F. Tison Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease Eur. J. Neurosci. 19 2004 3266 3276 (Pubitemid 38859544)
61. R.J. Dobbs, A. Charlett, A.G. Purkiss, S.M. Dobbs, C. Weller, and D.W. Peterson Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism Acta Neurol. Scand. 100 1999 34 41 (Pubitemid 29292549)
62. F. Dolle, C. Luus, A. Reynolds, and M. Kassiou Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography Curr. Med. Chem. 16 2009 2899 2923
63. Y. Du, Z. Ma, S. Lin, R.C. Dodel, F. Gao, K.R. Bales, L.C. Triarhou, E. Chernet, K.W. Perry, D.L. Nelson, S. Luecke, L.A. Phebus, F.P. Bymaster, and S.M. Paul Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 98 2001 14669 14674 (Pubitemid 33121449)
64. G. Dutta, P. Zhang, and B. Liu The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery Fundam. Clin. Pharmacol. 22 2008 453 464
65. B.A. Faucheux, A.M. Bonnet, Y. Agid, and E.C. Hirsch Blood vessels change in the mesencephalon of patients with Parkinson's disease Lancet 353 1999 981 982 (Pubitemid 29132612)
66. D.L. Feinstein, M.T. Heneka, V. Gavrilyuk, C.D. Russo, G. Weinberg, and E. Galea Noradrenergic regulation of inflammatory gene expression in brain Neurochem. Int. 41 2002 357 365
67. B. Ferger, A. Leng, A. Mura, B. Hengerer, and J. Feldon Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum J. Neurochem. 89 2004 822 833 (Pubitemid 38684730)
68. J.C. Fernandez-Checa, N. Kaplowitz, C. Garcia-Ruiz, A. Colell, M. Miranda, M. Mari, E. Ardite, and A. Morales GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect Am. J. Physiol. 273 1997 G7 17
69. C.C. Ferrari, and R. Tarelli Parkinson's disease and systemic inflammation Parkinsons Dis. 2011 2011 436813
70. C.C. Ferrari, M.C. Pott Godoy, R. Tarelli, M. Chertoff, A.M. Depino, and F.J. Pitossi Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra Neurobiol. Dis. 24 2006 183 193 (Pubitemid 44437611)
71. I. Ferrer, A. Martinez, R. Blanco, E. Dalfo, and M. Carmona Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease J. Neural Transm. 118 2011 821 839
72. R. Field, S. Campion, C. Warren, C. Murray, and C. Cunningham Systemic challenge with the TLR3 agonist poly I: C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration Brain Behav. Immun. 24 2010 996 1007
73. U. Fiszer, E. Mix, S. Fredrikson, V. Kostulas, T. Olsson, and H. Link Gamma delta+ T cells are increased in patients with Parkinson's disease J. Neurol. Sci. 121 1994 39 45
74. F. Fornai, A.B. di Poggio, A. Pellegrini, S. Ruggieri, and A. Paparelli Noradrenaline in Parkinson's disease: from disease progression to current therapeutics Curr. Med. Chem. 14 2007 2330 2334 (Pubitemid 47618041)
75. J.J. Gagne, and M.C. Power Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis Neurology 74 2010 995 1002
76. H.M. Gao, and J.S. Hong Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression Trends Immunol. 29 2008 357 365
77. X. Gao, H. Chen, M.A. Schwarzschild, and A. Ascherio Use of ibuprofen and risk of Parkinson disease Neurology 76 2011 863 869
78. K.A. Gauss, L.K. Nelson-Overton, D.W. Siemsen, Y. Gao, F.R. DeLeo, and M.T. Quinn Role of NF-kappaB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-alpha J. Leukoc. Biol. 82 2007 729 741 (Pubitemid 47367165)
79. A. Gerhard, N. Pavese, G. Hotton, F. Turkheimer, M. Es, A. Hammers, K. Eggert, W. Oertel, R.B. Banati, and D.J. Brooks In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease Neurobiol. Dis. 21 2006 404 412 (Pubitemid 43099863)
80. M. Gesi, P. Soldani, F.S. Giorgi, A. Santinami, I. Bonaccorsi, and F. Fornai The role of the locus coeruleus in the development of Parkinson's disease Neurosci. Biobehav. Rev. 24 2000 655 668 (Pubitemid 30625131)
81. A. Ghosh, A. Roy, X. Liu, J.H. Kordower, E.J. Mufson, D.M. Hartley, S. Ghosh, R.L. Mosley, H.E. Gendelman, and K. Pahan Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 104 2007 18754 18759 (Pubitemid 350210769)
82. L.C. Gleeson, K.J. Ryan, É.W. Griffin, T.J. Connor, and A. Harkin The β2-adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity Brain Behav. Immun. 24 2010 1354 1361
83. P.H. Gordon, D.H. Moore, R.G. Miller, J.M. Florence, J.L. Verheijde, C. Doorish, J.F. Hilton, G.M. Spitalny, R.B. MacArthur, H. Mitsumoto, H.E. Neville, K. Boylan, T. Mozaffar, J.M. Belsh, J. Ravits, R.S. Bedlack, M.C. Graves, L.F. McCluskey, R.J. Barohn, and R. Tandan Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial Lancet Neurol. 6 2007 1045 1053 (Pubitemid 350116691)
84. M. Grilli, M. Pizzi, M. Memo, and P. Spano Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation Science 274 1996 1383 1385 (Pubitemid 26391464)
85. D.B. Hancock, E.R. Martin, J.M. Stajich, R. Jewett, M.A. Stacy, B.L. Scott, J.M. Vance, and W.K. Scott Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease Arch. Neurol. 64 2007 576 580 (Pubitemid 46588348)
86. C.H. Hawkes, K. Del Tredici, and H. Braak Parkinson's disease: a dual-hit hypothesis Neuropathol. Appl. Neurobiol. 33 2007 599 614 (Pubitemid 350076090)
87. Y. He, S. Appel, and W. Le Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum Brain Res. 909 2001 187 193 (Pubitemid 32710132)
88. S.S. Hebert, and B. De Strooper Molecular biology. miRNAs in neurodegeneration Science 317 2007 1179 1180
89. B. Hemmer, S. Cepok, D. Zhou, and N. Sommer Multiple sclerosis - a coordinated immune attack across the blood brain barrier Curr. Neurovasc. Res. 1 2004 141 150
90. M.T. Heneka, V. Gavrilyuk, G.E. Landreth, M.K. O'Banion, G. Weinberg, and D.L. Feinstein Noradrenergic depletion increases inflammatory responses in brain: effects on IκB and HSP70 expression J. Neurochem. 85 2003 387 398 (Pubitemid 36438334)
91. M.T. Heneka, F. Nadrigny, T. Regen, A. Martinez-Hernandez, L. Dumitrescu-Ozimek, D. Terwel, D. Jardanhazi-Kurutz, J. Walter, F. Kirchhoff, U.K. Hanisch, and M.P. Kummer Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine Proc. Natl. Acad. Sci. U. S. A. 107 2010 6058 6063
92. M.A. Hernan, G. Logroscino, and L.A. Garcia Rodriguez Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease Neurology 66 2006 1097 1099 (Pubitemid 44044799)
93. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 2009 382 397
94. J.J. Hoozemans, R. Veerhuis, A.J. Rozemuller, and P. Eikelenboom The pathological cascade of Alzheimer's disease: the role of inflammation and its therapeutic implications Drugs Today (Barc.) 38 2002 429 443 (Pubitemid 34733622)
95. S. Hunot, F. Boissiere, B. Faucheux, B. Brugg, A. Mouatt-Prigent, Y. Agid, and E.C. Hirsch Nitric oxide synthase and neuronal vulnerability in Parkinson's disease Neuroscience 72 1996 355 363 (Pubitemid 26111202)
96. S. Hunot, B. Brugg, D. Ricard, P.P. Michel, M.P. Muriel, M. Ruberg, B.A. Faucheux, Y. Agid, and E.C. Hirsch Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease Proc. Natl. Acad. Sci. U. S. A. 94 1997 7531 7536 (Pubitemid 27345350)
97. R.L. Hunter, N. Dragicevic, K. Seifert, D.Y. Choi, M. Liu, H.C. Kim, W.A. Cass, P.G. Sullivan, and G. Bing Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system J. Neurochem. 100 2007 1375 1386
98. K. Imamura, N. Hishikawa, M. Sawada, T. Nagatsu, M. Yoshida, and Y. Hashizume Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathol. 106 2003 518 526 (Pubitemid 37441607)
99. H. Ischiropoulos, and J.S. Beckman Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest. 111 2003 163 169 (Pubitemid 36105911)
100. A. Ishikawa, and H. Takahashi Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism J. Neurol. 245 1998 P4 P9
101. H. Jang, D.A. Boltz, R.G. Webster, and R.J. Smeyne Viral parkinsonism Biochim. Biophys. Acta 1792 2009 714 721
102. H. Jang, D. Boltz, K. Sturm-Ramirez, K.R. Shepherd, Y. Jiao, R. Webster, and R.J. Smeyne Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration Proc. Natl. Acad. Sci. U. S. A. 106 2009 14063 14068
103. L.F. Jarskog, H. Xiao, M.B. Wilkie, J.M. Lauder, and J.H. Gilmore Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro Int. J. Dev. Neurosci. 15 1997 711 716 (Pubitemid 27478191)
104. P. Jenner Oxidative stress in Parkinson's disease Ann. Neurol. 53 Suppl. 3 2003 S26 S36
105. P. Jenner, and C.W. Olanow Understanding cell death in Parkinson's disease Ann. Neurol. 44 1998 S72 S84
106. P. Jenner, D.T. Dexter, J. Sian, A.H. Schapira, and C.D. Marsden Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group Ann. Neurol. 32 Suppl. 1992 S82 S87
107. L.C. Johnston, X. Su, K. Maguire-Zeiss, K. Horovitz, I. Ankoudinova, D. Guschin, P. Hadaczek, H.J. Federoff, K. Bankiewicz, and J. Forsayeth Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease Mol. Ther. 16 2008 1392 1399
108. E. Junn, K.W. Lee, B.S. Jeong, T.W. Chan, J.Y. Im, and M.M. Mouradian Repression of alpha-synuclein expression and toxicity by microRNA-7 Proc. Natl. Acad. Sci. U. S. A. 106 2009 13052 13057
109. H. Kettenmann, R. Banati, and W. Walz Electrophysiological behavior of microglia Glia 7 1993 93 101
110. S.U. Kim, and J. de Vellis Microglia in health and disease J. Neurosci. Res. 81 2005 302 313 (Pubitemid 41359284)
111. H.S. Kim, and Y.H. Suh Minocycline and neurodegenerative diseases Behav. Brain Res. 196 2009 168 179
112. W.G. Kim, R.P. Mohney, B. Wilson, G.H. Jeohn, B. Liu, and J.S. Hong Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia J. Neurosci. 20 2000 6309 6316 (Pubitemid 30658427)
113. Y.S. Kim, S.S. Kim, J.J. Cho, D.H. Choi, O. Hwang, D.H. Shin, H.S. Chun, M.F. Beal, and T.H. Joh Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia J. Neurosci. 25 2005 3701 3711
114. H.J. Kim, N. Hawke, and A.S. Baldwin NF-kappaB and IKK as therapeutic targets in cancer Cell Death Differ. 13 2006 738 747
115. Y.S. Kim, D.H. Choi, M.L. Block, S. Lorenzl, L. Yang, Y.J. Kim, S. Sugama, B.P. Cho, O. Hwang, S.E. Browne, S.Y. Kim, J.S. Hong, M.F. Beal, and T.H. Joh A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation FASEB J. 21 2007 179 187 (Pubitemid 46052555)
116. J. Kim, K. Inoue, J. Ishii, W.B. Vanti, S.V. Voronov, E. Murchison, G. Hannon, and A. Abeliovich A MicroRNA feedback circuit in midbrain dopamine neurons Science 317 2007 1220 1224
117. C. Knott, G. Stern, and G.P. Wilkin Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2 Mol. Cell Neurosci. 16 2000 724 739 (Pubitemid 32062060)
118. E. Kopp, and S. Ghosh Inhibition of NF-kappa B by sodium salicylate and aspirin Science 265 1994 956 959
119. J.B. Koprich, C. Reske-Nielsen, P. Mithal, and O. Isacson Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease J. Neuroinflamm. 5 2008 8
120. R. Kortekaas, K.L. Leenders, J.C. van Oostrom, W. Vaalburg, J. Bart, A.T. Willemsen, and N.H. Hendrikse Blood-brain barrier dysfunction in parkinsonian midbrain in vivo Ann. Neurol. 57 2005 176 179 (Pubitemid 40179854)
121. I. Kurkowska-Jastrzebska, M. Babiuch, I. Joniec, A. Przybylkowski, A. Czlonkowski, and A. Czlonkowska Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice Int. Immunopharmacol. 2 2002 1213 1218
122. I. Kurkowska-Jastrzebska, T. Litwin, I. Joniec, A. Ciesielska, A. Przybylkowski, A. Czlonkowski, and A. Czlonkowska Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease Int. Immunopharmacol. 4 2004 1307 1318 (Pubitemid 39094405)
123. I. Kurkowska-Jastrzebska, A. Czlonkowski, and A. Czlonkowska Ibuprofen and the mouse model of Parkinson's disease Ann. Neurol. 59 2006 988 989 (Pubitemid 43830934)
124. N. Laflamme, and S. Rivest Effects of systemic immunogenic insults and circulating proinflammatory cytokines on the transcription of the inhibitory factor kappaB alpha within specific cellular populations of the rat brain J. Neurochem. 73 1999 309 321 (Pubitemid 29289140)
125. N. Laflamme, S. Lacroix, and S. Rivest An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia J. Neurosci. 19 1999 10923 10930 (Pubitemid 30235736)
126. Y. Lampl, M. Boaz, R. Gilad, M. Lorberboym, R. Dabby, A. Rapoport, M. Anca-Hershkowitz, and M. Sadeh Minocycline treatment in acute stroke: an open-label, evaluator-blinded study Neurology 69 2007 1404 1410 (Pubitemid 47511461)
127. J.W. Langston, L.S. Forno, J. Tetrud, A.G. Reeves, J.A. Kaplan, and D. Karluk Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure Ann. Neurol. 46 1999 598 605 (Pubitemid 29466438)
128. F.N. Lauw, D. Pajkrt, C.E. Hack, M. Kurimoto, S.J. van Deventer, and T. van der Poll Proinflammatory effects of IL-10 during human endotoxemia J. Immunol. 165 2000 2783 2789 (Pubitemid 30660729)
129. Z. Ling, D.A. Gayle, S.Y. Ma, J.W. Lipton, C.W. Tong, J.S. Hong, and P.M. Carvey In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain Mov Disord. 17 2002 116 124 (Pubitemid 36041267)
130. Z.D. Ling, Q. Chang, J.W. Lipton, C.W. Tong, T.M. Landers, and P.M. Carvey Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain Neuroscience 124 2004 619 628 (Pubitemid 38258285)
131. Z. Ling, Y. Zhu, C.W. Tong, J.A. Snyder, J.W. Lipton, and P.M. Carvey Prenatal lipopolysaccharide does not accelerate progressive dopamine neuron loss in the rat as a result of normal aging Exp. Neurol. 216 2009 312 320
132. C.M. Long-Smith, A.M. Sullivan, and Y.M. Nolan The influence of microglia on the pathogenesis of Parkinson's disease Prog. Neurobiol. 89 2009 277 287
133. C.M. Long-Smith, L. Collins, A. Toulouse, A.M. Sullivan, and Y.M. Nolan Interleukin-1beta contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro J. Neuroimmunol. 226 2010 20 26
134. A. Lyons, E.J. Downer, S. Crotty, Y.M. Nolan, K.H. Mills, and M.A. Lynch CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4 J. Neurosci. 27 2007 8309 8313 (Pubitemid 47219605)
135. D.N. Mannel Advances in sepsis research derived from animal models Int. J. Med. Microbiol. 297 2007 393 400 (Pubitemid 47188049)
136. M.R. Marien, F.C. Colpaert, and A.C. Rosenquist Noradrenergic mechanisms in neurodegenerative diseases: a theory Brain Res. Rev. 45 2004 38 78 (Pubitemid 38520015)
137. A.L. McCormack, S.K. Mak, J.M. Henderson, D. Bumcrot, M.J. Farrer, and D.A. Di Monte Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra PLoS One 5 2010 e12122
138. M.K. McCoy, T.N. Martinez, K.A. Ruhn, D.E. Szymkowski, C.G. Smith, B.R. Botterman, K.E. Tansey, and M.G. Tansey Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease J. Neurosci. 26 2006 9365 9375 (Pubitemid 44396849)
139. M.K. McCoy, K.A. Ruhn, T.N. Martinez, F.E. McAlpine, A. Blesch, and M.G. Tansey Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats Mol. Ther. 16 2008 1572 1579
140. P.L. McGeer, and E.G. McGeer Inflammation and the degenerative diseases of aging Ann. N. Y. Acad. Sci. 1035 2004 104 116 (Pubitemid 40362329)
141. P.L. McGeer, S. Itagaki, B.E. Boyes, and E.G. McGeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 1988 1285 1291
142. P.L. McGeer, C. Schwab, A. Parent, and D. Doudet Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration Ann. Neurol. 54 2003 599 604 (Pubitemid 37346066)
143. E.N. McNamee, K.M. Ryan, D. Kilroy, and T.J. Connor Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1β-induced neurotoxicity Eur. J. Pharmacol. 626 2010 219 228
144. E.N. McNamee, É.W. Griffin, K.M. Ryan, K.J. Ryan, S. Heffernan, A. Harkin, and T.J. Connor Noradrenaline acting at β-adrenoceptors induces expression of IL-1β and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex Neuropharmacology 59 2010 37 48
145. E.N. McNamee, K.M. Ryan, É.W. Griffin, R.E. González-Reyes,
146. R. Menon, K.F. Swan, T.W. Lyden, N.S. Rote, and S.J. Fortunato Expression of inflammatory cytokines (interleukin-1 beta and interleukin-6) in amniochorionic membranes Am. J. Obstet. Gynecol. 172 1995 493 500
147. L.M. Metz, D. Li, A. Traboulsee, M.L. Myles, P. Duquette, J. Godin, M. Constantin, and V.W. Yong Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial Mult. Scler. 15 2009 1183 1194
148. U. Meyer, A. Engler, L. Weber, M. Schedlowski, and J. Feldon Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy Neuroscience 154 2008 701 709
149. U. Meyer, M. Nyffeler, B.K. Yee, I. Knuesel, and J. Feldon Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice Brain Behav. Immun. 22 2008 469 486 (Pubitemid 351451821)
150. Miller, A.-M., Deighan, B., Downer, E., Lyons, A., Henrich-Noack, P., Nolan, Y., Lynch, M.A., 2011. Analysis of the impact of CD200 on neurodegenerative diseases. In: Chuen-Chung Chang, R., (Ed), Neurodegenerative Diseases - Processes, Prevention, Protection and Monitoring. InTech, Available from: http://www.intechopen.com/articles/show/title/analysis-of-the-impact-of- cd200-on-neurodegenerative-diseases.
151. U.K. Misra, and J. Kalita Overview: Japanese encephalitis Prog. Neurobiol. 91 2010 108 120
152. J.A. Mitchell, P. Akarasereenont, C. Thiemermann, R.J. Flower, and J.R. Vane Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase Proc. Natl. Acad. Sci. U. S. A. 90 1993 11693 11697 (Pubitemid 24008705)
153. M. Mogi, M. Harada, T. Kondo, P. Riederer, H. Inagaki, M. Minami, and T. Nagatsu Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients Neurosci. Lett. 180 1994 147 150
154. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neurosci. Lett. 165 1994 208 210
155. M. Mogi, M. Harada, T. Kondo, P. Riederer, and T. Nagatsu Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication J. Neural Transm. 103 1996 1077 1081 (Pubitemid 26383837)
156. M. Mogi, A. Togari, T. Kondo, Y. Mizuno, O. Komure, S. Kuno, H. Ichinose, and T. Nagatsu Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain J. Neural Transm. 107 2000 335 341 (Pubitemid 30162695)
157. M. Mogi, T. Kondo, Y. Mizuno, and T. Nagatsu p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain Neurosci. Lett. 414 2007 94 97 (Pubitemid 46241643)
158. K.P. Mohanakumar, D. Muralikrishnan, and B. Thomas Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity Brain Res. 864 2000 281 290 (Pubitemid 30235109)
159. R.B. Mounsey, and P. Teismann Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection Parkinsons Dis. 2011 2010 617472
160. M.P. Mount, A. Lira, D. Grimes, P.D. Smith, S. Faucher, R. Slack, H. Anisman, S. Hayley, and D.S. Park Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons J. Neurosci. 27 2007 3328 3337 (Pubitemid 46474138)
161. T. Muller, D. Blum-Degen, H. Przuntek, and W. Kuhn Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease Acta Neurol. Scand. 98 1998 142 144 (Pubitemid 28351288)
162. S. Nadeau, and S. Rivest Glucocorticoids play a fundamental role in protecting the brain during innate immune response J. Neurosci. 23 2003 5536 5544 (Pubitemid 36807829)
163. NINDS-NET-PD-Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease Neurology 66 2006 664 671
164. NINDS-NET-PD-Investigators A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results Clin. Neuropharmacol. 31 2008 141 150
165. Y. Nolan, E. Vereker, A.M. Lynch, and M.A. Lynch Evidence that lipopolysaccharide-induced cell death is mediated by accumulation of reactive oxygen species and activation of p38 in rat cortex and hippocampus Exp. Neurol. 184 2003 794 804 (Pubitemid 38182808)
166. A. O'Garra, F.J. Barrat, A.G. Castro, A. Vicari, and C. Hawrylowicz Strategies for use of IL-10 or its antagonists in human disease Immunol. Rev. 223 2008 114 131 (Pubitemid 351986180)
167. J.B. O'Sullivan, K.M. Ryan, N.M. Curtin, A. Harkin, and T.J. Connor Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration Int. J. Neuropsychopharmacol. 12 2009 687 699
168. A. Ogata, K. Tashiro, S. Nukuzuma, K. Nagashima, and W.W. Hall A rat model of Parkinson's disease induced by Japanese encephalitis virus J. Neurovirol. 3 1997 141 147 (Pubitemid 27182507)
169. A. Ogata, K. Tashiro, and S. Pradhan Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis Neurology 55 2000 602 (Pubitemid 30647273)
170. T. Okada, N. Matsuzaki, K. Sawai, T. Nobunaga, K. Shimoya, K. Suzuki, N. Taniguchi, F. Saji, and Y. Murata Chorioamnionitis reduces placental endocrine functions: the role of bacterial lipopolysaccharide and superoxide anion J. Endocrinol. 155 1997 401 410 (Pubitemid 27524047)
171. C.F. Orr, D.B. Rowe, and G.M. Halliday An inflammatory review of Parkinson's disease Prog. Neurobiol. 68 2002 325 340 (Pubitemid 36071510)
172. Y. Ouchi, S. Yagi, M. Yokokura, and M. Sakamoto Neuroinflammation in the living brain of Parkinson's disease Parkinsonism Relat. Disord. 15 Suppl. 3 2009 S200 S204
173. P.J. Paddison, A.A. Caudy, and G.J. Hannon Stable suppression of gene expression by RNAi in mammalian cells Proc. Natl. Acad. Sci. U. S. A. 99 2002 1443 1448 (Pubitemid 34136512)
174. V. Papadopoulos, M. Baraldi, T.R. Guilarte, T.B. Knudsen, J.J. Lacapere, P. Lindemann, M.D. Norenberg, D. Nutt, A. Weizman, M.R. Zhang, and M. Gavish Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function Trends Pharmacol. Sci. 27 2006 402 409 (Pubitemid 44069585)
175. C.H. Park, E. Carboni, P.L. Wood, and K.W. Gee Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line Glia 16 1996 65 70 (Pubitemid 26350512)
176. V.H. Perry The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease Brain Behav. Immun. 18 2004 407 413 (Pubitemid 38950834)
177. V.H. Perry Contribution of systemic inflammation to chronic neurodegeneration Acta Neuropathol. 120 2010 277 286
178. V.H. Perry, C. Cunningham, and C. Holmes Systemic infections and inflammation affect chronic neurodegeneration Nat. Rev. Immunol. 7 2007 161 167 (Pubitemid 46174862)
179. V.H. Perry, J.A. Nicoll, and C. Holmes Microglia in neurodegenerative disease Nat. Rev. Neurol. 6 2010 193 201
180. P. Piccini, N. Pavese, P. Hagell, J. Reimer, A. Bjorklund, W.H. Oertel, N.P. Quinn, D.J. Brooks, and O. Lindvall Factors affecting the clinical outcome after neural transplantation in Parkinson's disease Brain 128 2005 2977 2986 (Pubitemid 41746650)
181. G. Porras, and E. Bezard Preclinical development of gene therapy for Parkinson's disease Exp. Neurol. 209 2008 72 81
182. C.M. Poser, C.J. Huntley, and J.D. Poland Para-encephalitic parkinsonism. Report of an acute case due to coxsackie virus type B 2 and re-examination of the etiologic concepts of postencephalitic parkinsonism Acta Neurol. Scand. 45 1969 199 215
183. M.C. Pott Godoy, R. Tarelli, C.C. Ferrari, M.I. Sarchi, and F.J. Pitossi Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease Brain 131 2008 1880 1894 (Pubitemid 351957456)
184. M.R. Pranzatelli, S.H. Mott, S.G. Pavlakis, J.A. Conry, and E.D. Tate Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder Pediatr. Neurol. 10 1994 131 140 (Pubitemid 24113315)
185. L. Qian, J.S. Hong, and P.M. Flood Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10 J. Neural Transm. Suppl. 2006 367 371 (Pubitemid 44622225)
186. L. Qian, P. Flood, and J.-S. Hong Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy J. Neural Transm. 117 2010 971 979
187. L. Qian, H.-m. Wu, S.-H. Chen, D. Zhang, S.F. Ali, L. Peterson, B. Wilson, R.-B. Lu, J.-S. Hong, and P.M. Flood β2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway J. Immunol. 186 2011 4443 4454
188. L. Qin, X. Wu, M.L. Block, Y. Liu, G.R. Breese, J.S. Hong, D.J. Knapp, and F.T. Crews Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration Glia 55 2007 453 462 (Pubitemid 46383175)
189. Y. Qu, L. Franchi, G. Nunez, and G.R. Dubyak Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages J. Immunol. 179 2007 1913 1925
190. L.P. Quinn, B. Crook, M.E. Hows, M. Vidgeon-Hart, H. Chapman, N. Upton, A.D. Medhurst, and D.J. Virley The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B Br. J. Pharmacol. 154 2008 226 233 (Pubitemid 351620404)
191. E.M. Quintero, L. Willis, R. Singleton, N. Harris, P. Huang, N. Bhat, and A.C. Granholm Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease Brain Res. 1093 2006 198 207 (Pubitemid 43946408)
192. D. Rail, C. Scholtz, and M. Swash Post-encephalitic Parkinsonism: current experience J. Neurol. Neurosurg. Psychiatr. 44 1981 670 676 (Pubitemid 11028113)
193. R.M. Ransohoff, and A.E. Cardona The myeloid cells of the central nervous system parenchyma Nature 468 2010 253 262
194. R.M. Ransohoff, and V.H. Perry Microglial physiology: unique stimuli, specialized responses Annu. Rev. Immunol. 27 2009 119 145
195. M. Reale, C. Iarlori, A. Thomas, D. Gambi, B. Perfetti, M. Di Nicola, and M. Onofrj Peripheral cytokines profile in Parkinson's disease Brain Behav. Immun. 23 2009 55 63
196. M. Rentzos, C. Nikolaou, E. Andreadou, G.P. Paraskevas, A. Rombos, M. Zoga, A. Tsoutsou, F. Boufidou, E. Kapaki, and D. Vassilopoulos Circulating interleukin-15 and RANTES chemokine in Parkinson's disease Acta Neurol. Scand. 116 2007 374 379 (Pubitemid 350045501)
197. A.D. Reynolds, J.G. Glanzer, I. Kadiu, M. Ricardo-Dukelow, A. Chaudhuri, P. Ciborowski, R. Cerny, B. Gelman, M.P. Thomas, R.L. Mosley, and H.E. Gendelman Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease J. Neurochem. 104 2008 1504 1525 (Pubitemid 351316759)
198. A.D. Reynolds, D.K. Stone, R.L. Mosley, and H.E. Gendelman Nitrated α-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets J. Immunol. 182 2009 4137 4149
199. A.D. Reynolds, D.K. Stone, R.L. Mosley, and H.E. Gendelman Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells J. Proteome Res. 8 2009 3497 3511
200. A.D. Reynolds, D.K. Stone, J.A.L. Hutter, E.J. Benner, R.L. Mosley, and H.E. Gendelman Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease J. Immunol. 184 2010 2261 2271
201. I. Rite, A. Machado, J. Cano, and J.L. Venero Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons J. Neurochem. 101 2007 1567 1582 (Pubitemid 46848862)
202. R.L. Robinson, S. Shahida, N. Madan, S. Rao, and N. Khardori Transient parkinsonism in West Nile virus encephalitis Am. J. Med. 115 2003 252 253 (Pubitemid 37338156)
203. K.S. Rommelfanger, and D. Weinshenker Norepinephrine: the redheaded stepchild of Parkinson's disease Biochem. Pharmacol. 74 2007 177 190 (Pubitemid 46890808)
204. K.S. Rommelfanger, D. Weinshenker, and G.W. Miller Reduced MPTP toxicity in noradrenaline transporter knockout mice J. Neurochem. 91 2004 1116 1124 (Pubitemid 39587450)
205. A. Samii, M. Etminan, M.O. Wiens, and S. Jafari NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies Drugs Aging 26 2009 769 779
206. E.P. Sampaio, E.N. Sarno, R. Galilly, Z.A. Cohn, and G. Kaplan Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes J. Exp. Med. 173 1991 699 703
207. R. Sanchez-Pernaute, A. Ferree, O. Cooper, M. Yu, A.L. Brownell, and O. Isacson Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease J. Neuroinflammation 1 2004 6
208. J.A. Saugstad MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration J. Cereb. Blood Flow Metab. 30 2010 1564 1576
209. R. Savica, W.A. Rocca, and J.E. Ahlskog When does Parkinson disease start? Arch. Neurol. 67 2010 798 801
210. M. Sawada, K. Imamura, and T. Nagatsu Role of cytokines in inflammatory process in Parkinson's disease J. Neural Transm. Suppl. 2006 373 381 (Pubitemid 44622226)
211. R.I. Scheinman, A. Gualberto, C.M. Jewell, J.A. Cidlowski, and A.S. Baldwin Jr. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors Mol. Cell Biol. 15 1995 943 953
212. N. Schintu, L. Frau, M. Ibba, P. Caboni, A. Garau, E. Carboni, and A.R. Carta PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease Eur. J. Neurosci. 29 2009 954 963
213. S. Schmidt, B. Linnartz, S. Mendritzki, T. Sczepan, M. Lubbert, C.C. Stichel, and H. Lubbert Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria Hum. Mol. Genet. 20 2011 1197 1211
214. H. Schwarz, C. Hickey, C. Zimmerman, P. Mazzoni, C. Moskowitz, D. Rosas, M. McCall, J. Sanchez-Ramos, J. Perlmutter, A. Wernle, D. Higgins, C. Nickerson, S. Evans, R. Kumar, D. Miracle, L. Dure, D. Pendley, K. Anderson, M. Cines, T. Ashizawa, P. Stanton, H. Fernandez, M. Suelter, B. Leavitt, J. Decolongon, and H.S.G. Domino A futility study of minocycline in Huntington's disease Mov. Dis. 25 2010 2219 2224
215. S. Shan, T. Hong-Min, F. Yi, G. Jun-Peng, F. Yue, T. Yan-Hong, Y. Yun-Ke, L. Wen-Wei, W. Xiang-Yu, M. Jun, W. Guo-Hua, H. Ya-Ling, L. Hua-Wei, and C. Ding-Fang NEW evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease Neurobiol. Aging 32 2011 443 458
216. H. Shoji, M. Watanabe, S. Itoh, H. Kuwahara, and F. Hattori Japanese encephalitis and parkinsonism J. Neurol. 240 1993 59 60
217. J. Sian, D.T. Dexter, A.J. Lees, S. Daniel, Y. Agid, F. Javoy-Agid, P. Jenner, and C.D. Marsden Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann. Neurol. 36 1994 348 355 (Pubitemid 24280055)
218. R.W. Smithells, and C.G. Newman Recognition of thalidomide defects J. Med. Genet. 29 1992 716 723
219. D.T. Stephenson, D.A. Schober, E.B. Smalstig, R.E. Mincy, D.R. Gehlert, and J.A. Clemens Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat J. Neurosci. 15 1995 5263 5274
220. H.B. Stolp, and K.M. Dziegielewska Review: role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases Neuropathol. Appl. Neurobiol. 35 2009 132 146
221. D.K. Stone, A.D. Reynolds, R.L. Mosley, and H.E. Gendelman Innate and adaptive immunity for the pathobiology of Parkinson's disease Antioxid. Redox Signal. 11 2009 2151 2166
222. J.D. Stone, A.S. Chervin, and D.M. Kranz T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity Immunology 126 2009 165 176
223. G. Stypula, J. Kunert-Radek, H. Stepien, K. Zylinska, and M. Pawlikowski Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease Neuroimmunomodulation 3 1996 131 134 (Pubitemid 26373868)
224. M. Takahashi, T. Yamada, S. Nakajima, K. Nakajima, T. Yamamoto, and H. Okada The substantia nigra is a major target for neurovirulent influenza A virus J. Exp. Med. 181 1995 2161 2169
225. M.G. Tansey, and M.S. Goldberg Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention Neurobiol. Dis. 37 2010 510 518
226. M.G. Tansey, M.K. McCoy, and T.C. Frank-Cannon Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention Exp. Neurol. 208 2007 1 25 (Pubitemid 47603240)
227. D.R. Thakker, D. Hoyer, and J.F. Cryan Interfering with the brain: use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders Pharmacol. Ther. 109 2006 413 438 (Pubitemid 43132820)
228. S. Theodore, S. Cao, P.J. McLean, and D.G. Standaert Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease J. Neuropathol. Exp. Neurol. 67 2008 1149 1158
229. N.A. Thornberry, H.G. Bull, J.R. Calaycay, K.T. Chapman, A.D. Howard, M.J. Kostura, D.K. Miller, S.M. Molineaux, J.R. Weidner, and J. Aunins A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes Nature 356 1992 768 774
230. H. Tilg, C. van Montfrans, A. van den Ende, A. Kaser, S.J. van Deventer, S. Schreiber, M. Gregor, O. Ludwiczek, P. Rutgeerts, C. Gasche, J.C. Koningsberger, L. Abreu, I. Kuhn, M. Cohard, A. LeBeaut, P. Grint, and G. Weiss Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma Gut 50 2002 191 195 (Pubitemid 34087930)
231. M. Tomas-Camardiel, I. Rite, A.J. Herrera, R.M. de Pablos, J. Cano, A. Machado, and J.L. Venero Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system Neurobiol. Dis. 16 2004 190 201 (Pubitemid 38569810)
232. A. Toulouse, and A.M. Sullivan Progress in Parkinson's disease-where do we stand? Prog. Neurobiol. 85 2008 376 392
233. K.J. Tracey The inflammatory reflex Nature 420 2002 853 859 (Pubitemid 36019638)
234. W. Tse, M.G. Cersosimo, J.M. Gracies, S. Morgello, C.W. Olanow, and W. Koller Movement disorders and AIDS: a review Parkinsonism Relat. Disord. 10 2004 323 334 (Pubitemid 38942788)
235. D. Tweedie, K. Sambamurti, and N.H. Greig TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets Curr. Alzheimer Res. 4 2007 378 385 (Pubitemid 47421968)
236. E. Vereker, E. O'Donnell, A. Lynch, A. Kelly, Y. Nolan, and M.A. Lynch Evidence that interleukin-1beta and reactive oxygen species production play a pivotal role in stress-induced impairment of LTP in the rat dentate gyrus Eur. J. Neurosci. 14 2001 1809 1819 (Pubitemid 35463699)
237. J.T. Walsh, and J. Kipnis Regulatory T cells in CNS injury: the simple, the complex and the confused Trends Mol. Med. 17 2011 541 547
238. J.H. Walters Postencephalitic Parkinson syndrome after meningoencephalitis due to coxsackie virus group B, type 2 New Eng. J. Med. 263 1960 744 747
239. G. Wang, J.M. van der Walt, G. Mayhew, Y.J. Li, S. Zuchner, W.K. Scott, E.R. Martin, and J.M. Vance Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein Am. J. Hum. Genet. 82 2008 283 289
240. S. Wang, J.Y. Yan, Y.K. Lo, P.M. Carvey, and Z. Ling Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide Brain Res. 1265 2009 196 204
241. X.J. Wang, S. Zhang, Z.Q. Yan, Y.X. Zhao, H.Y. Zhou, Y. Wang, G.Q. Lu, and J.D. Zhang Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: Roles of aging, superoxide, NADPH oxidase, and p38 MAPK Free Radic. Biol. Med 50 2011 1094 1106
242. C. Weller, N. Oxlade, S.M. Dobbs, R.J. Dobbs, A. Charlett, and I.T. Bjarnason Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism FEMS Immunol. Med. Microbiol. 44 2005 129 135 (Pubitemid 41378983)
243. H. Wilms, P. Rosenstiel, J. Sievers, G. Deuschl, L. Zecca, and R. Lucius Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease FASEB J. 17 2003 500 502
244. A. Winkeler, R. Boisgard, A. Martin, and B. Tavitian Radioisotopic imaging of neuroinflammation J. Nucl. Med. 51 2010 1 4
245. D.C. Wu, V. Jackson-Lewis, M. Vila, K. Tieu, P. Teismann, C. Vadseth, D.K. Choi, H. Ischiropoulos, and S. Przedborski Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease J. Neurosci. 22 2002 1763 1771 (Pubitemid 35386294)
246. T. Yamada, P.L. McGeer, and E.G. McGeer Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins Acta Neuropathol. 84 1992 100 104
247. L. Yang, S. Sugama, J.W. Chirichigno, J. Gregorio, S. Lorenzl, D.H. Shin, S.E. Browne, Y. Shimizu, T.H. Joh, M.F. Beal, and D.S. Albers Minocycline enhances MPTP toxicity to dopaminergic neurons J. Neurosci. Res. 74 2003 278 285 (Pubitemid 37193714)
248. Y. Yang, S. Kaul, D. Zhang, V. Anantharam, and A.G. Kanthasamy Suppression of caspase-3-dependent proteolytic activation of protein kinase C delta by small interfering RNA prevents MPP+-induced dopaminergic degeneration Mol. Cell Neurosci. 25 2004 406 421 (Pubitemid 38366406)
249. T. Yasuda, M. Fukuda-Tani, T. Nihira, K. Wada, N. Hattori, Y. Mizuno, and H. Mochizuki Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease Exp. Neurol. 206 2007 308 317 (Pubitemid 47094775)
250. W. Zhang, T. Wang, Z. Pei, D.S. Miller, X. Wu, M.L. Block, B. Wilson, Y. Zhou, J.S. Hong, and J. Zhang Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease FASEB J. 19 2005 533 542 (Pubitemid 40471244)
251. F. Zhang, L. Qian, P.M. Flood, J.S. Shi, J.S. Hong, and H.M. Gao Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity J. Pharmacol. Exp. Ther. 333 2010 822 833
252. Y. Zhou, Y. Su, B. Li, F. Liu, J.W. Ryder, X. Wu, P.A. Gonzalez-DeWhitt, V. Gelfanova, J.E. Hale, P.C. May, S.M. Paul, and B. Ni Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho Science 302 2003 1215 1217 (Pubitemid 37421027)